Filing Flows

Filing Flows › X4 Pharmaceuticals (XFOR) › Next earnings date

X4 Pharmaceuticals (XFOR) earnings: beat the estimate

X4 Pharmaceuticals (XFOR) reported on Nov 4, 2026 and beat the EPS estimate: −$0.16 against −$0.19 (+14.0%). Revenue was $2.8M for Q3 2026, +75% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+14.0% vs estimate
Beat rate100%

The last report

X4 Pharmaceuticals reported revenue of $2.8M for the third quarter 2026 (+75% Y/Y), net loss $20.2M. How it makes money → · Every quarter →

X4 Pharmaceuticals: EPS against the estimate, last 5 reportsX4 Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.84−$0.69Nov 25−$0.35−$0.22Mar 26−$0.20−$0.16May 26−$0.18−$0.13Aug 26−$0.19−$0.16Nov 26
Latest (Nov 26): Estimate −$0.19, Reported −$0.16.
XFOR: the stock's move on each reportXFOR: the stock's move on each reportAug 6, 2026+11.8%May 6, 2026+2.1%Mar 17, 2026+13.8%Nov 5, 2025-11.7%

X4 Pharmaceuticals' latest quarter

X4 Pharmaceuticals, Q3 2026: revenue $2.8M (+75% year over year), operating margin -714.0%, net loss $20.2M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did X4 Pharmaceuticals beat earnings?

X4 Pharmaceuticals (XFOR) reported on Nov 4, 2026 and beat the EPS estimate: −$0.16 against −$0.19 (+14.0%).

When does XFOR report earnings?

The next date is not set yet.

Does X4 Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.